<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="41918">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01980524</url>
  </required_header>
  <id_info>
    <org_study_id>HYPOTESIS</org_study_id>
    <secondary_id>2013-002656-32</secondary_id>
    <nct_id>NCT01980524</nct_id>
  </id_info>
  <brief_title>The Impact of Free Fatty Acid (FFA-) Suppression on Myocardial Lipids and Function in Patients With Type 2 Diabetes</brief_title>
  <acronym>HYPOTESIS</acronym>
  <official_title>HYPOglycemia Linked to Cardiac sTEatoSIS? - Identifying Mechanisms That Explain Adverse Cardiovascular Outcome Associated With Intensive Glucose Control in Patients With Diabetes (HYPOTESIS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is evidence that inhibition of FFA-release by acipimox is associated with a
      significant decrease in myocardial lipid content (MYCL) as well as the ejection fraction (as
      a marker of systolic left ventricular function) in healthy subjects, indicating, that the
      heart is dependent on a constant supply of free fatty acids in order to guarantee normal
      cardiac function, and it further indicates, that the heart is not able to cover its energy
      demand by switching to glucose oxidation.

      Since that phenomenon, better known as &quot;metabolic inflexibility&quot; has been mainly described
      in patients with diabetes, we aim to investigate the impact of FFA-inhibition on MYCL and
      cardiac function in patients with overt type 2 diabetes.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <primary_completion_date type="Anticipated">November 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>MYCL</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ejection fraction</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>stroke volume</measure>
    <time_frame>2 hours</time_frame>
    <safety_issue>No</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>acipimox+</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>250 mg at 0 and 180 minutes (one day)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>acipimox-</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>1 Tablet at 0 and 180 minutes (one day)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acipimox</intervention_name>
    <arm_group_label>acipimox+</arm_group_label>
    <arm_group_label>acipimox-</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 2 Diabetes

          -  HbA1C &gt;6%

        Exclusion Criteria:

          -  Insulin therapy (except: BOT=basal supported oral therapy)

          -  Known heart disease including coronary artery disease, cardiomyopathy, history of
             cardiac surgery

          -  Known intolerance against niacins

          -  Known contra-indications against magnetic resonance (MR-) examinations
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Krebs, Prof.MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna, Dept. of Internal Medicine III, Division of Endocrinology and Metabolism</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yvonne Winhofer, MD PhD</last_name>
    <phone>+43 1 40400 4311</phone>
    <email>yvonne.winhofer@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Peter Wolf, MD</last_name>
    <phone>+43 1 40400 2069</phone>
    <email>peter.wolf@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Division of Endocrinology and Metabolism, Internal Medicine III, Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Wolf, MD</last_name>
      <phone>+43 1 40400 2069</phone>
      <email>peter.wolf@meduniwien.ac.at</email>
    </contact>
    <investigator>
      <last_name>Michael Krebs, Prof.MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Yvonne Winhofer, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 4, 2013</lastchanged_date>
  <firstreceived_date>October 26, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Prof. Dr. Michael Krebs</investigator_full_name>
    <investigator_title>Prof.MD</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acipimox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
